Regardless of country-level income classification, medications for the secondary prevention of CVD remains underutilized and ...
An analysis of the PURE study shows some gains but “little to no improvement in most places over time,” says Philip Joseph.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback